Cargando…

Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report

A 2-year-and-7-month-old boy underwent an emergent reconstruction surgery of the right ventricle-pulmonary artery (RV-PA) conduit. Although he was successfully weaned from cardiopulmonary bypass (CPB) after reconstruction of the RV-PA conduit, the bleeding continued despite the massive transfusion o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishihara, Mariko, Miyamoto, Yoshikazu, Taniguchi, Akihiro, Kinouchi, Keiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818693/ https://www.ncbi.nlm.nih.gov/pubmed/29497641 http://dx.doi.org/10.1186/s40981-015-0012-7

Ejemplares similares

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))
por: Bartosh, Nicole S, et al.
Publicado: (2013)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Evaluation of the role of recombinant activated factor VII (NovoSeven) as a rescue haemostatic therapy in postcardiopulmonary bypass surgical patients
por: Chen, Z, et al.
Publicado: (2007)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump
por: Rexen, Per, et al.
Publicado: (2019)

Use of NovoSeven(® )in cases with massive bleeding following surgery with extracorporeal circulation
por: Dementieva, I, et al.
Publicado: (2004)

Eptacog-α/prednisone/rituximab: No response: case report
Publicado: (2021)

Timely ‘off-label’ use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature
por: Burad, Jyoti, et al.
Publicado: (2012)

Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(®))
por: Viuff, D., et al.
Publicado: (2008)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

Experience of NovoSeven administration in management of coagulopathic bleedings after surgical interventions with extracorporeal circulation
por: Dzybinskaya, E, et al.
Publicado: (2006)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery
por: Barua, Anupama, et al.
Publicado: (2011)

Combination of Novoseven and Feiba in Hemophiliac Patients with Inhibitors
por: Malkan, Umit Yavuz, et al.
Publicado: (2018)

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Successful hemostasis in refractory alveolar hemorrhage using low-dose recombinant activated factor VII
por: Selickman, John, et al.
Publicado: (2022)

Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
por: Habib, Aly Makram, et al.
Publicado: (2016)

Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur
por: Miatech, Jennifer L, et al.
Publicado: (2021)

A Case of “Anaphylaxis” to NovoSeven in a Hemophiliac Patient
por: Wang, Andy, et al.
Publicado: (2023)

Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report
por: Godier, Anne, et al.
Publicado: (2018)

Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
por: Klitgaard, Thomas, et al.
Publicado: (2006)

Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
por: AlGahtani, Farjah H., et al.
Publicado: (2010)

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
por: Johansson, Pär I, et al.
Publicado: (2010)

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery
por: Michalska, G, et al.
Publicado: (2009)

Use of recombinant activated factor VII for bleeding following resection of mediastinal angiosarcoma
por: Arora, D, et al.
Publicado: (2011)

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
por: Chang, Zhi-gang, et al.
Publicado: (2020)

Guidelines-associated decrease in mortality with recombinant activated factor VII for refractory hemorrhage
por: Schneider, AS, et al.
Publicado: (2009)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis
por: Abuhasna, Said D., et al.
Publicado: (2012)

Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding
por: Habib, Aly Makram
Publicado: (2016)

Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™)
por: Goudarzi Pour, Kourosh, et al.
Publicado: (2016)

Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven(®)) utilization at a large academic medical center
por: Marsh, Kassandra, et al.
Publicado: (2020)

Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII
por: Jones, Simon, et al.
Publicado: (2021)

Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation
por: Hollis, Allison L., et al.
Publicado: (2016)

Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever
por: Manoj, Edirisooriya Maddumage, et al.
Publicado: (2014)

Experience of NovoSeven administration in the management of severe haemorrhage following cardiac surgery of nonhaemophilic patients
por: Michalska, G, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vm48j96pd2ol3mjnapu553qnmv